Loading clinical trials...

Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types) | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)

Clinical Pharmacological Study of FYU-981 Administered to Hyperuricemic Outpatients With or Without Gout

NCT03375632•Mochida Pharmaceutical Company, Ltd.

View on ClinicalTrials.gov

Summary

To investigate the pharmacodynamics and safety of FYU-981 administered orally once a day for 14 weeks, to uric acid-overproduction type or uric acid-underexcretion type of male hyperuricemic outpatients with or without gout.

Eligibility

Age

20 - No limit years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Serum urate level:
•* \>= 7.0mg/dL in patients with gouty nodule or with history of gout, or \>=8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or \>= 9.0mg/dL
•Disease type in the classification of hyperuricemia: Uric acid-overproduction type or Uric acid-underexcretion type
•Outpatients

Exclusion Criteria

•Gouty arthritis within 14 days before randomized allocation

Locations (1)

Mochida Investigational sites

Tokyo, Japan

Key Dates

Start Date

January 4, 2018

Primary Completion Date

May 29, 2018

Completion Date

June 5, 2018

Last Updated

September 24, 2018

Enrollment

ACTUAL participants

Conditions

Hyperuricemia With or Without Gout

Interventions

FYU-981

DRUG

The Effects of a Probiotic Food Supplement in Hyperuricaemia

NCT07141888

Hyperuricemia With or Without Gout

View study

COMPLETEDPHASE3

Study of FYU-981 in Hyperuricemia With or Without Gout

NCT03006445

Hyperuricemia With or Without Gout

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 24, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions